• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 2 Mar

    Soligenix to Present at the Q1 Virtual Investor Summit

    PRINCETON, N.J., March 2, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Senior Vice President and Chief Financial Officer, Jonathan Guarino, has… Read More..

    Share this:
  • 2 Mar

    ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease

    Transgenic mouse model reflects latest scientific understanding of disease – toxic oligomers of amyloid create cognitive deficit TORONTO, Ontario and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins… Read More..

    Share this:
  • 2 Mar

    Codex DNA to Report Fourth Quarter 2021 Financial Results on Tuesday, March 22, 2022

    SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its fourth quarter 2021 financial results on Tuesday, March 22, 2022, after the market closes. In conjunction with the release, management will host… Read More..

    Share this:
« Previous 1 … 225 226 227 228 229 … 244 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact